Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Somatostatinoma 2Carcinoma, Islet Cell 2Breast Neoplasms 2Vipoma 1Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Insulinoma 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gastrinoma 1Congenital Abnormalities 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

avelumab 2Capecitabine 2veliparib 1domatinostat 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Radiosurgery 1Omacor 1Leucovorin 1Ipilimumab 1Fluorouracil 1Cyclophosphamide 1Complementary Therapies 1Cisplatin 1Biological Therapy 1Bevacizumab 1ALT-803 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Merkel Cell × Biological Therapy × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡